Drug Profile
Research programme: antibody therapies - Crucell/LFB Biotechnologies
Latest Information Update: 16 Jun 2011
Price :
$50
*
At a glance
- Originator Crucell; LFB Biotechnologies
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 25 Jul 2007 Preclinical trials in Undefined indication in France (unspecified route)